What Is Psilocybin-Assisted Therapy?
Psilocybin is the psychoactive compound in “magic mushrooms.” In clinical settings, synthetic psilocybin is administered in precisely measured doses alongside intensive psychotherapy — before, during, and after the psychedelic experience.
The results from clinical trials have been extraordinary. A landmark 2022 study in the New England Journal of Medicine showed that psilocybin therapy produced response rates of 70%+ and remission rates above 50% in treatment-resistant depression — in just two sessions. These are among the highest efficacy numbers ever recorded for any depression treatment.
How psilocybin works in the brain
Psilocybin activates 5-HT2A serotonin receptors, triggering massive increases in neural connectivity — parts of the brain that don't normally communicate begin exchanging information. The Default Mode Network (DMN), which is hyperactive in depression and responsible for rumination, temporarily quiets.
This creates a window of extreme neuroplasticity — the brain becomes temporarily more flexible and open to new patterns of thinking. Combined with skilled therapy, this window allows patients to process trauma, break rumination cycles, and develop new perspectives on their lives.
Current Legal Status (2026)
Oregon
Legal through regulated psilocybin service centers since January 2023. Licensed facilitators guide sessions. No prescription needed.
Colorado
Natural Medicine Health Act (2022) is building a regulated framework. Healing centers expected to open 2024-2025.
FDA Track
Breakthrough Therapy designation from FDA. Phase III trials by COMPASS Pathways and Usona Institute are ongoing. Possible approval 2025-2027.
Psilocybin vs. TMS
| Factor | Psilocybin | TMS |
|---|---|---|
| FDA Status | Not approved (Breakthrough) | FDA Cleared (2008) |
| Sessions | 1-2 dosing sessions | 30-36 sessions |
| Response Rate | 70%+ (trials) | 50-60% |
| Availability | Oregon only + trials | Nationwide, 1000s of clinics |
| Insurance | Not covered | Widely covered |
| Psychosis Risk | Contraindicated | Low risk |
| Experience | Intense psychedelic (6-8 hrs) | Mild scalp tapping (20 min) |
Who Should Consider Psilocybin
- Treatment-resistant depression that hasn’t responded to medications, therapy, or TMS
- Willingness to engage in intensive psychological preparation and integration work
- No history of psychotic disorders (schizophrenia, schizoaffective, bipolar with psychosis)
- Access to a legal, regulated setting (Oregon, clinical trial, or eventually broader FDA approval)
- Openness to a profoundly altered state of consciousness
Who Should Choose TMS Instead
- Anyone who wants an FDA-cleared, insurance-covered treatment available nationwide
- Patients with psychotic disorder history (absolute contraindication for psilocybin)
- Those who want treatment without altered consciousness or psychedelic effects
- People who need a treatment they can do during lunch break, not an 8-hour session
- Patients in states where psilocybin isn’t legally accessible
For more on how TMS compares, read our TMS vs. Psilocybin guide. Use our clinic finder to explore TMS providers available today.